Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

DJL Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$610,069

98 payments

Through program year 2025, DJL Clinical Research is reported as receiving $610,069 in research payments, across 98 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $38,910 12
2024 Research $101,772 18
2023 Research $136,413 11
2022 Research $68,339 11
2021 Research $99,331 25
2020 Research $55,814 12
2019 Research $109,490 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $200,129 9 payments
  2. Sanofi US Services Inc. $171,701 40 payments
  3. AstraZeneca UK Limited $46,720 5 payments
  4. Astellas Pharma Global Development $32,962 20 payments
  5. Celgene Corporation $30,548 2 payments
  6. Biogen, Inc. $26,462 1 payment
  7. Regeneron Pharmaceuticals, Inc. $23,376 5 payments
  8. Novartis Pharmaceuticals Corporation $19,738 1 payment
  9. Amgen Inc. $16,798 2 payments
  10. GlaxoSmithKline, LLC. $15,556 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Phase II Study SLE - A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BMS-986256 in Participants with Active Systemic Lupus Erythematosus $133,148 3 payments
  2. Randomized, Double-blind, Placebo Controlled, Proof of Concept Study Assessing the Efficacy and Safety of the RIPK1-inhibitor SAR443122 in Patients With Moderate to Severe Subacute or Discoid/Chronic Cutaneous Lupus Erythematosus $64,924 16 payments
  3. Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients na $32,967 4 payments
  4. A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms $32,962 20 payments
  5. A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis $31,098 3 payments
  6. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cc-220 in Subjects With Active Systemic Lupus Erythematosus (Cc-220-Sle-002) $30,548 2 payments
  7. The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre Randomised Double blind Placebo Controlled Phase 3 Extension Study to Characterise the Long term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus $29,923 4 payments
  8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care $26,462 1 payment
  9. A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With SLE $26,256 1 payment
  10. Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab $21,026 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record